[MCEMENT] QoQ Cumulative Quarter Result on 31-Mar-2013 [#1]

Stock
[MCEMENT] MALAYAN CEMENT BERHAD
Announcement Date
22-May-2013
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2013
Quarter
31-Mar-2013 [#1]
Profit Trend
QoQ- -84.44%
YoY- -16.22%
Quarter Report
Latest QR
Upcoming QR
MCEMENT's Result
MCEMENT's Financial Summary
View:
Show?
Cumulative Result
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
Revenue 2,852,400 2,101,826 1,373,813 644,941 2,740,062 2,049,916 1,341,161 65.15%
PBT 514,890 344,819 183,405 73,369 469,752 330,858 197,501 89.09%
Tax -147,772 -88,468 -47,345 -18,929 -120,262 -87,501 -50,709 103.62%
NP 367,118 256,351 136,060 54,440 349,490 243,357 146,792 83.94%
-
NP to SH 366,630 255,965 135,743 54,304 349,005 243,283 146,911 83.67%
-
Tax Rate 28.70% 25.66% 25.81% 25.80% 25.60% 26.45% 25.68% -
Total Cost 2,485,282 1,845,475 1,237,753 590,501 2,390,572 1,806,559 1,194,369 62.77%
-
Net Worth 3,211,847 3,177,859 3,126,877 3,109,883 3,169,362 3,135,374 3,101,386 2.35%
Dividend
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
Div 348,374 67,975 67,975 67,975 314,387 203,926 152,945 72.85%
Div Payout % 95.02% 26.56% 50.08% 125.18% 90.08% 83.82% 104.11% -
Equity
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
Net Worth 3,211,847 3,177,859 3,126,877 3,109,883 3,169,362 3,135,374 3,101,386 2.35%
NOSH 849,695 849,695 849,695 849,695 849,695 849,695 849,695 0.00%
Ratio Analysis
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
NP Margin 12.87% 12.20% 9.90% 8.44% 12.75% 11.87% 10.95% -
ROE 11.41% 8.05% 4.34% 1.75% 11.01% 7.76% 4.74% -
Per Share
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
RPS 335.70 247.36 161.68 75.90 322.48 241.25 157.84 65.15%
EPS 43.20 30.10 16.00 6.40 41.10 28.60 17.30 83.75%
DPS 41.00 8.00 8.00 8.00 37.00 24.00 18.00 72.85%
NAPS 3.78 3.74 3.68 3.66 3.73 3.69 3.65 2.35%
Adjusted Per Share Value based on latest NOSH - 849,695
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
RPS 213.28 157.16 102.72 48.22 204.88 153.28 100.28 65.15%
EPS 27.41 19.14 10.15 4.06 26.10 18.19 10.98 83.71%
DPS 26.05 5.08 5.08 5.08 23.51 15.25 11.44 72.82%
NAPS 2.4016 2.3762 2.338 2.3253 2.3698 2.3444 2.319 2.35%
Price Multiplier on Financial Quarter End Date
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
Date 31/12/13 30/09/13 28/06/13 29/03/13 31/12/12 28/09/12 29/06/12 -
Price 8.57 9.42 10.18 9.96 9.62 8.90 7.30 -
P/RPS 2.55 3.81 6.30 13.12 2.98 3.69 4.62 -32.63%
P/EPS 19.86 31.27 63.72 155.84 23.42 31.08 42.22 -39.43%
EY 5.03 3.20 1.57 0.64 4.27 3.22 2.37 64.92%
DY 4.78 0.85 0.79 0.80 3.85 2.70 2.47 55.10%
P/NAPS 2.27 2.52 2.77 2.72 2.58 2.41 2.00 8.78%
Price Multiplier on Announcement Date
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
Date 25/02/14 19/11/13 27/08/13 22/05/13 20/02/13 22/11/12 28/08/12 -
Price 8.54 9.85 9.11 10.98 9.19 9.62 8.60 -
P/RPS 2.54 3.98 5.63 14.47 2.85 3.99 5.45 -39.80%
P/EPS 19.79 32.70 57.02 171.80 22.37 33.60 49.74 -45.81%
EY 5.05 3.06 1.75 0.58 4.47 2.98 2.01 84.50%
DY 4.80 0.81 0.88 0.73 4.03 2.49 2.09 73.80%
P/NAPS 2.26 2.63 2.48 3.00 2.46 2.61 2.36 -2.83%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment